AV
AVCT.LSE Avacta Group PLC
- Market cap
- GBX 252M
- P/E
- -
- P/B
- 68.16x
- ROE
- -2,018.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AVCT.LSE undervalued?
Graham numberThe Graham number of Avacta Group PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avacta Group PLC fundamental analysis
No fundamental analysis for Avacta Group PLC yet.
Avacta Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the ex…
Full company profileAvacta Group PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avacta Group PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.17M | 2.74M | 2.76M | 3.89M | 2.14M | 2.94M | 9.65M | 2.85M | 113K | 113K | 224K |
| Gross Profit | 24.0K | 211K | -164K | 86.1K | -973K | -2.50M | 7.24M | 2.84M | 113K | 113K | -2.02M |
| Operating Income | -5.66M | -7.97M | -9.45M | -12.7M | -16.9M | -29.1M | -25.5M | -22.0M | -32.6M | -30.3M | -58.4M |
| EBITDA | -4.42M | -6.40M | -8.36M | -8.40M | -16.4M | -26.7M | -34.8M | -14.1M | -17.7M | -29.0M | -56.2M |
| Net Income | -4.65M | -6.37M | -8.83M | -11.0M | -18.9M | -26.3M | -36.9M | -24.9M | -52.8M | -38.4M | -76.1M |
| EPS | -0.07 | -0.09 | -0.13 | - | -0.08 | -0.11 | -0.14 | -0.09 | -0.16 | -0.10 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 37.6M | 31.6M | 23.5M | 28.4M | 67.5M | 47.0M | 92.6M | 73.2M | 48.3M | 29.4M | 30.9M |
| Total Liabilities | 1.70M | 1.66M | 2.04M | 2.60M | 5.53M | 5.78M | 74.2M | 51.4M | 39.0M | 26.9M | 27.2M |
| Shareholders' Equity | 35.9M | 29.9M | 21.4M | 25.8M | 61.9M | 41.2M | 18.4M | 21.8M | 9.28M | 2.48M | 3.77M |
| Cash & Short-term Investments | 19.5M | 13.2M | 5.22M | 8.79M | 47.9M | 26.2M | 41.8M | 16.6M | 12.9M | 16.9M | 20.3M |
| Total Debt | - | - | - | 823K | 2.04M | 1.70M | 62.9M | 23.5M | 22.9M | 14.9M | 19.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.23M | -4.24M | -5.47M | -13.0M | -10.6M | -20.5M | -16.4M | -14.9M | -23.6M | -24.8M | -57.1M |
| Capital Expenditure | 4.63M | 2.13M | 2.52M | 2.53M | 1.67M | 1.31M | 594K | 1.26M | 339K | 53.0K | 64.0K |
| Free Cash Flow | -8.86M | -6.37M | -7.99M | -15.5M | -12.3M | -21.8M | -17.0M | -16.1M | -23.9M | -24.8M | -57.2M |
| Ratios | |||||||||||
| ROE | -13.0% | -21.3% | -41.2% | -42.7% | -30.5% | -63.8% | -200.3% | -114.4% | -569.3% | -1,549.9% | -2,018.9% |
| ROA | -12.4% | -20.2% | -37.6% | -38.8% | -28.0% | -56.0% | -39.9% | -34.1% | -109.5% | -130.5% | -245.9% |
| Net Profit Margin | -214.6% | -232.8% | -319.5% | -283.3% | -881.1% | -894.8% | -382.7% | -875.0% | -46,761.9% | -33,961.1% | -33,969.6% |
| Debt to Equity | - | - | - | 0.03x | 0.03x | 0.04x | 3.41x | 1.08x | 2.47x | 6.02x | 5.27x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avacta Group PLC dividends
Avacta Group PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jan 26, 2016.
Who owns Avacta Group PLC
- Insiders 3.16%
- Institutions 3.11%
- Public & others 93.72%
- Shares outstanding 438M
- Free float 441M
Avacta Group PLC company profile
- Company name
- Avacta Group PLC
- Ticker
- AVCT.LSE
- ISIN
- GB00BYYW9G87
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- Scale Space White City Imperial College Campus, London, United Kingdom, W12 7RZ
- Phone
- 44 203 9110353
- Website
- avacta.com
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Avacta Group PLC management
10- Dr. Christina Marie Coughlin B.S., M.D., Ph.D.CEO & Executive Director · born 1970
- Mr. Brian M. HahnCFO & Company Secretary · born 1974
- Ms. Karen HarrisonChief Operating Officer
- Mr. Francis WilsonChief Scientific Officer
- Ms. Emma WrightGroup In-House Counsel
- Mr. Michael VinegradGroup Communications Director
- Mr. R. Craig Slater FCAChief Operating Officer of Diagnostics · born 1964
- Mr. David WilsonChief Commercial Officer of Diagnostics
- Ms. Anne McGurkJoint Managing Director of Launch Diagnostics
- Mr. Sebastien GoenenChief Operating Officer of Coris BioConcept